The end of a monopoly
For twenty years the default was to make it in China. Tariffs, pandemic shocks and US–China tension have ended the monopoly, and the corporate response has a name: China+1 — keep China, but add at least one more base to spread the risk. The strategy is now mainstream across electronics, pharmaceuticals and machinery. Most of the resulting factory floor lands in Vietnam, India, Mexico or Malaysia, where labour is cheap. Singapore, one of the most expensive places in Asia to operate, wins a different and narrower slice — and the data shows it is winning.
What China+1 is, and why it accelerated
China+1 is not about leaving China. It is about no longer depending on it alone. A firm keeps its Chinese plants for the domestic market and cost-sensitive lines, then builds a parallel capability elsewhere so that a tariff, an export control or a port closure cannot halt supply. Three forces turned a hedge into a rush. First, tariffs: successive rounds of duties made China-made goods structurally more expensive for the American market. Second, supply-chain risk, seared in during 2020–2022 when single-country dependence proved fragile. Third, geopolitics: export controls on advanced chips and equipment made concentration in China a strategic liability, not just a commercial one. For anything touching semiconductors or defence-adjacent technology, a China-only footprint became close to untenable.
Where Singapore fits — and where it does not
Singapore competes for none of the cost-driven diversification. On wages, land and space it loses to every regional alternative. It competes instead for the work where the buyer’s real worry is not price but trust — and on that ground it has advantages that are hard to replicate. The first is IP protection and rule of law: Singapore ranks at or near the top of Asian jurisdictions for enforcing contracts and defending intellectual property, which matters when the asset being localised is a chip design or a drug formulation. The second is high-end capability: the workforce, suppliers and research base to run advanced fabs, biologics lines and precision machining. The third is connectivity — Changi, the port, and free-trade agreements with most major economies. The one thing Singapore does not offer is low cost, and it does not pretend to. For a multi-billion-dollar foundry or a biologics plant, cost is the smallest line in the risk calculation.
The 2025 investment data captures the shift with unusual clarity. In EDB’s commitments, the United States’ share of fixed-asset investment fell sharply while China’s rose, and Chinese firms accounted for roughly half of business expenditure. Diversification runs both ways: American multinationals de-risk out of China into Singapore, and Chinese firms build a trusted, neutral base in Singapore to serve customers wary of China-only supply. Total commitments still reached S$14.2bn — the source changed, the volume held.
The sectors the diversification landed in
Three clusters absorbed most of the high-value flow. Semiconductors are the clearest case. Singapore already supplies about a tenth of the world’s chips and a fifth of the world’s chipmaking equipment, and recent commitments read as a de-risking roll-call — new foundry and packaging capacity landing precisely to spread geographic risk. Pharmaceuticals are the second: China+1 in pharma is driven by the same logic as chips — a refusal to source critical active ingredients from a single country — and Singapore’s biomedical cluster, which grew 16.3% in 2025, has the biologics and complex-API capability to take the high-value end. Precision manufacturing is the third: as anchor plants localise, they need local suppliers of precision components, tooling and automation, and Singapore’s precision-engineering cluster is the spine that lets a diversifying multinational build a real supply chain here rather than fly every part in.
The buyer’s real blocker
Strip away the macro story and the diversification decision comes down to one question in the buyer’s head: can I trust this supplier’s real capacity? Moving a critical line to an unfamiliar country means betting on a factory the buyer has never walked through, run by people they have never met, quoting a capability they cannot independently verify. A polished PDF and a certificate do not settle it. The fear of an unknown supplier over-promising is the single biggest brake on China+1 — more than cost, more than logistics.
This is precisely the gap a verified, video-led record is built to close. A written directory asserts capability; it cannot prove it. Film of the actual shop floor — the machines running, the cleanroom in operation, the people on the line, the certifications visible in context — lets a buyer in Munich or Milwaukee assess a Singapore supplier’s real capacity before spending a dollar on travel. The discipline that every published fact is true and traceable is not editorial nicety; it is the exact reassurance a de-risking buyer needs. Trust is the currency of China+1, and a verifiable record trades in it.
EnterpriseSG, GlobalConnect and ITAP
Singapore does not leave the matchmaking to chance. Enterprise Singapore runs an overseas network of centres across major markets and its GlobalConnect programme to link local suppliers with foreign buyers and partners — the institutional plumbing that turns a diversification intent into a signed contract. The annual shop window is Industrial Transformation Asia-Pacific (ITAP), held each October in Singapore and drawing around 16,000 industry buyers and professionals. For a manufacturer weighing a Singapore base, ITAP is where the record, the suppliers and the buyers meet in one room — the physical counterpart to the digital record, and a natural moment for a verified profile to earn an enquiry.
The honest caveats
Singapore is not the answer for every China+1 decision, and pretending otherwise would fail the buyer. Cost is the obvious constraint: wages and operating expenses run well above every regional alternative, so anything price-sensitive goes to Vietnam, India or Malaysia. Land is scarce and expensive — JTC rations industrial space, and a sprawling low-density plant is simply not viable. Labour is tight: the resident workforce is small, foreign-worker quotas are capped, and a firm cannot solve a bottleneck by hiring a thousand people quickly. The correct read is that Singapore is the “+1” for the top slice of the value chain, not the volume. A manufacturer typically pairs a Singapore base — for the IP-critical, high-margin, trust-dependent work — with a lower-cost site elsewhere for scale. Positioned that way, the constraints are the reason Singapore stays specialised.
Outlook
The structural tailwind is strong and unlikely to reverse. Export controls on advanced semiconductors, persistent US–China tension and hard-learned lessons about single-country dependence all point the same way — more diversification, and a disproportionate share of the high-value, IP-sensitive slice heading to trusted jurisdictions. Singapore is the most trusted address in Asia for exactly that work, and the 2025 investment figures show the flow is already arriving from both American and Chinese firms. The competitive question is no longer whether the work comes, but whether buyers can find and trust the right Singapore supplier fast enough to place it. That is a discovery-and-trust problem — and it is the problem a verified, video-led record exists to solve.